Products & Pipeline

IMGENEX India is developing affordable biosimilars to substitute high-cost branded biologics, alongside diagnostic kits used in clinical practice. Browse our therapeutic pipeline and diagnostic products below.

Therapeutic Preclinical

Biosimilar Trastuzumab

Originator: Herceptin (Genentech/Roche)

High-yield CHO-expressed biosimilar of Trastuzumab (Herceptin) for HER2-positive cancers, developed under BIRAC-DBT funding.

Learn more

Diagnostic Approved

ImCoV-Ag - Rapid Antigen Test for COVID-19

Originator: Co-developed by IMGENEX India and ICMR-RMRC, Bhubaneswar

Lateral flow chromatographic immunoassay for the qualitative detection of SARS-CoV-2 antigen in human nasopharyngeal swabs. Co-developed with ICMR-RMRC, Bhubaneswar.

Learn more

Diagnostic Approved

Beta-Thalassemia Mutation Detection Kit

Originator: Co-developed with NIIH-ICMR, Mumbai

Indigenous diagnostic kit to detect common Indian beta-thalassemia mutations. Released by ICMR in collaboration with National Institute Immunohematology, Mumbai.

Learn more

Therapeutic Discovery

Biosimilar Adalimumab

Originator: Humira (AbbVie)

Biosimilar program of Adalimumab (Humira), an anti-TNF-alpha monoclonal antibody used to treat a wide range of autoimmune conditions.

Learn more

Therapeutic Discovery

Biosimilar Bevacizumab

Originator: Avastin (Genentech/Roche)

Biosimilar program of Bevacizumab (Avastin), an anti-VEGF monoclonal antibody used in multiple solid tumour indications.

Learn more

Therapeutic Discovery

Biosimilar Ustekinumab

Originator: Stelara (Janssen)

Biosimilar program of Ustekinumab (Stelara), an IL-12/IL-23 inhibitor for psoriasis and inflammatory bowel disease.

Learn more

Therapeutic Discovery

Biosimilar Nivolumab

Originator: Opdivo (Bristol-Myers Squibb)

Biosimilar program of Nivolumab (Opdivo), an anti-PD-1 immune checkpoint inhibitor for multiple solid tumours.

Learn more